Panel request to review the data for entrectinib as a treatment option for NTRK gene fusion-positive sarcoma.

External request: Submission from Genentech, requesting the review of the data supporting the inclusion of entrectinib for the treatment of patients with NTRK gene fusion-positive sarcoma.

Based upon review of the data in the noted references, the panel consensus did not support the addition of entrectinib as a treatment option for NTRK gene fusion-positive sarcoma.


- See Submission for references.